ECM
OBIO icon

ExodusPoint Capital Management’s Orchestra BioMed OBIO Stock Holding History

ExodusPoint Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-95,635
Closed -$397K – 1938
2025
Q4 		$397K Buy
+95,635
New +$386K ﹤0.01% 1235
2021
Q1 		– Sell
-29,800
Closed -$382K – 2457
2020
Q4 		$382K Buy
+29,800
New +$340K ﹤0.01% 1409

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

ExodusPoint Capital Management's OBIO Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Orchestra BioMed (OBIO) in Q1 2026, closing a stake of 95,635 shares — an estimated $397K sold.

ExodusPoint Capital Management first reported a position in OBIO in Q4 2020 and held it in 2 quarters. The position peaked at $397K in Q4 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • ExodusPoint Capital Management reported no remaining Orchestra BioMed position as of Q1 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 95,635 Orchestra BioMed shares in Q1 2026, an estimated $397K.
  • ExodusPoint Capital Management first reported a position in Orchestra BioMed in Q4 2020 and held it in 2 quarters.
  • ExodusPoint Capital Management's Orchestra BioMed position peaked at $397K in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.